Rogaratinib 在 FGFR mRNA 表达筛选的晚期癌症患者中的 1 期剂量递增与扩展研究
这项 1 期研究评估了口服 pan-FGFR 抑制剂 rogaratinib 在晚期癌症患者中的安全性、耐受性、药代动力学和初步疗效。研究纳入 126 例患者,未达到最大耐受剂量,推荐 2 期剂量为 800 mg 每日两次;
要点
- Rogaratinib 推荐 2 期剂量为 800 mg 每日两次,未达到最大耐受剂量。
- 常见不良事件为高磷血症、腹泻和食欲下降,治疗相关死亡未发生。
核心结论
- Rogaratinib 耐受良好并在多种癌症类型中显示临床活性。
- FGFR mRNA 表达可能作为额外生物标志物,识别更广泛的 FGFR 抑制剂适用人群。
研究设计与样本
- 1 期剂量递增和剂量扩展研究,在德国、瑞士、韩国、新加坡、西班牙和法国的 22 个中心进行。
- 纳入 18 岁及以上、标准治疗无效、ECOG 体能状态 0-2、预期寿命至少 3 个月、至少一个可测量或可评估病灶的晚期癌症患者。
- 剂量递增阶段采用基于模型的剂量-反应分析(持续重新评估法),rogaratinib 口服每日两次,剂量范围 50-800 mg,连续 21 天为一周期。
- 剂量扩展阶段纳入 FGFR mRNA 过表达肿瘤患者,分为尿路上皮癌、头颈鳞癌、非小细胞肺癌和其他实体瘤四个队列。
- 共筛查 866 例患者 FGFR mRNA 表达,126 例接受治疗(剂量递增阶段 23 例未筛选患者,剂量扩展阶段 103 例 FGFR mRNA 过表达患者)。
主要发现
- 未报告剂量限制性毒性,未达到最大耐受剂量,800 mg 每日两次确定为推荐 2 期剂量。
- 任何级别最常见不良事件为高磷血症(77/126,61%)、腹泻(65/126,52%)和食欲下降(48/126,38%)。
- 3-4 级最常见不良事件为乏力(11/126,9%)和无症状性脂肪酶升高(10/126,8%)。
- 治疗相关严重不良事件报告于 5 例患者,无治疗相关死亡。
关键数值与推荐
- 推荐 2 期剂量为 rogaratinib 800 mg 每日两次口服。
- 15 例 FGFR mRNA 过表达且无明确 FGFR 基因畸变的肿瘤中,10 例(67%)有缓解。
临床怎么用
- Rogaratinib 在 FGFR mRNA 过表达晚期癌症中显示初步疗效,支持进一步研究 FGFR mRNA 作为生物标志物。
- 治疗期间需监测高磷血症、腹泻、食欲下降、乏力和脂肪酶升高等不良事件。
局限性
- 本研究为 1 期研究,样本量有限,疗效为初步结果。
- 剂量扩展阶段仅纳入 FGFR mRNA 过表达肿瘤患者,未与未筛选人群直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical activity of fibroblast growth factor receptor (FGFR) inhibitors seems restricted to cancers harbouring rare FGFR genetic aberrations. In preclinical studies, high tumour FGFR mRNA expression predicted response to rogaratinib, an oral pan-FGFR inhibitor. We aimed to assess the safety, maximum tolerated dose, recommended phase 2 dose, pharmacokinetics, and preliminary clinical activity of rogaratinib. METHODS: We did a phase 1 dose-escalation and dose-expansion study of rogaratinib in adults with advanced cancers at 22 sites in Germany, Switzerland, South Korea, Singapore, Spain, and France. Eligible patients were aged 18 years or older, and were ineligible for standard therapy, with an Eastern Cooperative Oncology Group performance status of 0-2, a life expectancy of at least 3 months, and at least one measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. During dose escalation, rogaratinib was administered orally twice daily at 50-800 mg in continuous 21-day cycles using a model-based dose-response analysis (continuous reassessment method). In the dose-expansion phase, all patients provided an archival formalin-fixed paraffin-embedded (FFPE) tumour biopsy or consented to a new biopsy at screening for the analysis of FGFR1-3 mRNA expression. In the dose-expansion phase, rogaratinib was given at the recommended dose for expansion to patients in four cohorts: urothelial carcinoma, head and neck squamous-cell cancer (HNSCC), non-small-cell lung cancer (NSCLC), and other solid tumour types. Primary endpoints were safety and tolerability, determination of maximum tolerated dose including dose-limiting toxicities and determination of recommended phase 2 dose, and pharmacokinetics of rogaratinib. Safety analyses were reported in all patients who received at least one dose of rogaratinib. Patients who completed cycle 1 or discontinued during cycle 1 due to an adverse event or dose-limiting toxicity were included in the evaluation of recommended phase 2 dose. Efficacy analyses were reported for all patients who received at least one dose of study drug and who had available post-baseline efficacy data. This ongoing study is registered with ClinicalTrials.gov, number NCT01976741, and is fully recruited. FINDINGS: Between Dec 30, 2013, and July 5, 2017, 866 patients were screened for FGFR mRNA expression, of whom 126 patients were treated (23 FGFR mRNA-unselected patients in the dose-escalation phase and 103 patients with FGFR mRNA-overexpressing tumours [52 patients with urothelial carcinoma, eight patients with HNSCC, 20 patients with NSCLC, and 23 patients with other tumour types] in the dose-expansion phase). No dose-limiting toxicities were reported and the maximum tolerated dose was not reached; 800 mg twice daily was established as the recommended phase 2 dose and was selected for the dose-expansion phase. The most common adverse events of any grade were hyperphosphataemia (in 77 [61%] of 126 patients), diarrhoea (in 65 [52%]), and decreased appetite (in 48 [38%]); and the most common grade 3-4 adverse events were fatigue (in 11 [9%] of 126 patients) and asymptomatic increased lipase (in 10 [8%]). Serious treatment-related adverse events were reported in five patients (decreased appetite and diarrhoea in one patient with urothelial carcinoma, and acute kidney injury [NSCLC], hypoglycaemia [other solid tumours], retinopathy [urothelial carcinoma], and vomiting [urothelial carcinoma] in one patient each); no treatment-related deaths occurred. Median follow-up after cessation of treatment was 32 days (IQR 25-36 days). In the expansion cohorts, 15 (15%; 95% CI 8·6-23·5) out of 100 evaluable patients achieved an objective response, with responses recorded in all four expansion cohorts (12 in the urothelial carcinoma cohort and one in each of the other three cohorts), and in ten (67%) of 15 FGFR mRNA-overexpressing tumours without apparent FGFR genetic aberration. INTERPRETATION: Rogaratinib was well tolerated and clinically active against several types of cancer. Selection by FGFR mRNA expression could be a useful additional biomarker to identify a broader patient population who could be eligible for FGFR inhibitor treatment. FUNDING: Bayer AG.
引用
- Schuler M, Cho BC, Sayehli CM, et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019. PMID: 31405822. doi:10.1016/S1470-2045(19)30412-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。